Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3Other 1Gynecologic 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Sexual Dysfunction, Physiological 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Depression 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1Anxiety Disorders 1

Interventions

Paclitaxel 153Carboplatin 123Bevacizumab 87Cisplatin 66pembrolizumab 58Taxes 51Gemcitabine 51liposomal doxorubicin 39Topotecan 37olaparib 31Immunoglobulin G 27Disulfides 26Cyclophosphamide 24Brachytherapy 22Docetaxel 21human papillomavirus vaccine, L1 type 16, 18 20niraparib 19Platinum 19Nivolumab 18Magnetic Resonance Spectroscopy 181,2-diaminocyclohexaneplatinum II citrate 18rucaparib 17durvalumab 16Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 16Doxorubicin 16Radiotherapy, Intensity-Modulated 14Radiation 13Albumin-Bound Paclitaxel 13fludarabine phosphate 12fludarabine 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Dehydroepiandrosterone × Gynecologic × Clear all
NCT01376349 2019-02-07

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

Alliance for Clinical Trials in Oncology

Phase 3 Completed
464 enrolled 8 charts
BreastGynecologicOther

Carcinoma, Ovarian Epithelial, Anxiety Disorders, Breast Neoplasms, Uterine Cervical Neoplasms, Depression, Fallopian Tube Neoplasms, Sexual Dysfunction, Physiological, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡